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CLINICAL RESEARCH
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Aims Histological studies support the important role of inflammation in the initiation and maintenance of atrial fibrillation
(AF). We describe a novel and safe technique of atrial biopsy during AF radiofrequency catheter ablation (RFCA) to
investigate the role of atrial tissue inflammation.
Methods
and results
We enrolled 70 consecutive patients (age 60+12 years, 49 males) undergoing RFCA for AF. The control group was
represented by 10 patients with Wolff–Parkinson–White syndrome undergoing trans-septal puncture. Atrial biop-
sies were obtained by washing the dilator and needle used for trans-septal puncture with 20 mL sterile phosphate-
buffered saline. The presence of intracytoplasmic C-reactive protein was assessed in formalin-fixed atrial specimens
by immunohistochemistry. A sufficient amount of atrial tissue was obtained in 23/70 (32%) patients with AF and in
4/10 (40%) of the control group. Intracytoplasmic localization of C-reactive protein was found in isolated atrial
cardiomyocytes in 11 (73%) of 15 patients with paroxysmal AF as compared with 2 (25%) of eight patients with
persistent AF (P ¼ 0.02).
Conclusion In this study, we demonstrate the safety and feasibility of a novel technique to obtain atrial specimens during routine
trans-septal puncture. Local inflammation assessed by atrial tissue localization of C-reactive protein is more likely
involved in paroxysmal rather than in persistent AF.
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Introduction
Atrial fibrillation (AF) is a growing public health burden because of
its increasing incidence, its potential for devastating clinical conse-
quences, and its complex and expensive treatment.1,2 Thus, new
prevention strategies are highly desirable. Histological and
biomarker studies support the notion of a robust link between
inflammatory status and AF.3 In particular, atrial specimens
obtained by endomyocardial biopsy (EMB) showed clusters of
lymphomononuclear cells compatible with diagnosis of myocarditis
in 66% of patients with lone AF.4 Furthermore, in patients with
non-valvular AF undergoing surgical thrombectomy with left
atrial appendectomy because of large thrombi, activated T lympho-
cytes were found in left atrial endocardium, supporting the role of
local inflammation as a potential trigger of AF.5 Thus, atrial EMB
may represent a valid tool to elucidate cellular and molecular
mechanisms of inflammation associated with AF. This procedure,
however, is currently indicated only in patients with atrial cardiac
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tumours,6 –9 while current guidelines recommend that it should
not be performed in the setting of unexplained AF,10 as the risks
are not counterbalanced by a clear clinical benefit. The safety of
trans-septal catheterization in the setting of radiofrequency
catheter ablation (RFCA) has been established by several
studies.11–13 Notably, its success rate when guided by intracardiac
echography has been reported to reach 100%.14 –16 Thus, as
trans-septal catheterization is routinely used for RFCA of AF, we
have developed a novel approach for assessing the histopathology
of AF using atrial specimens obtained during routine trans-septal
catheterization.
Methods
Patient characteristics
We prospectively enrolled 70 consecutive patients (mean age was
60+12 years, 49 males) with paroxysmal or persistent AF undergoing
antral pulmonary vein isolation. Atrial fibrillation was paroxysmal in 42
patients and persistent in 28 patients, according to the definition given
by the recent European Society of Cardiology guidelines.17 Exclusion
criteria included intercurrent infective and inflammatory disorders,
neoplastic disease, treatment with steroid or non-steroidal anti-
inflammatory agents other than aspirin (up to 100 mg daily), an
acute coronary syndrome within the month before catheter ablation
and patent foramen ovale. We also enrolled 10 control patients
(mean age 23+7 years, 3 females) with Wolff–Parkinson–White
(WPW) syndrome who underwent catheter ablation of left-sided
accessory pathways, without history of AF at the time of ablation.
The protocol was approved by the Ethic Committee of the Catholic
University of Sacred Heart and all patients provided written informed
consent.
Electrophysiological procedure
Before the procedure, computerized tomography scan of the heart
was performed in all patients to define the anatomy of the pulmonary
veins (PVs) and transthoracic echocardiography to assess left atrial par-
ameters. In all patients trans-septal catheterization was performed by
trans-septal assembly consisting of (i) 8F Preface sheath (Biosense
Webster, Diamond Bar, CA, USA), (ii) dilator, and (iii) Brockenbrough
needle. All patients underwent trans-septal puncture and AF ablation
using an intracardiac echocardiography-guided technique.18,19 We
also used dye injection to confirm the correct positioning of the
needle in the left atrium, as soon as the most distal part of the
dilator had passed the atrial septum at the fossa ovalis. Intracardiac
echocardiography-guided PVs antrum isolation was performed under
the guidance of Carto mapping system (Biosense Webster) in 65%
of patients and EnSite NavX mapping system (St Jude Medical, Inc.,
St Paul, MN, USA) in 35% of patients. Irrigated radiofrequency
energy was delivered with a target temperature of 438C and a
power between 25 and 35 W (Thermo Cool, Biosense Webster).
The electrophysiological endpoint was absence or dissociation of all
PVs potentials documented by circular mapping catheter (Lasso, Bio-
sense Webster) within the ipsilateral superior and inferior PVs and
along the PVs antrum.20 No additional lines were made in paroxysmal
and persistent AF patients.
Atrial specimens sampling
After single trans-septal puncture and advancement of trans-septal
assembly in the left atrium, the dilator and the needle were removed
and separately flushed with 10 mL of phosphate buffer solution (PBS
10× GIBCO, Invitrogen) in 20 mL tube. Trans-septal puncture was
performed in the septal region of the right atrium, from areas adjacent
to the fossa ovalis, as indicated by intracardiac echocardiography. After
this step, all patients were systematically anticoagulated with intrave-
nous heparin to reach an activated clotting time of 300–400 s. After
removal of PBS the atrial specimens were immersed in 10 cc of 10%
formalin.
Immunohistochemistry
The formalin-fixed, paraffin-embedded specimens were sectioned at
5 mm and stained with haematoxylin and eosin and with haematoxylin
and Van Gieson to confirm the presence of atrial cardiomyocytes. Sec-
tions from each specimen displaying atrial cardiomyocytes were cut at
5 mm, mounted on glass, and dried overnight at 378C. All sections
were then deparaffinized in xylene, rehydrated through a graded
alcohol series and washed in PBS, which was used also for all sub-
sequent washes and for antibody dilution. Endogenous peroxidase
activity was blocked by 5% hydrogen peroxide. For immunohistochem-
istry, tissue sections were heated twice in a microwave oven for 5 min
each at 700 W in citrate buffer (pH 6). The murine monoclonal anti-
body (clone C-reactive protein-8, IgG1, Sigma, St Louis, MO, USA)
directed against human C-reactive protein was used at 1:100 dilution
and incubated overnight at 48C. Then, the sections were processed
with the standard streptavidin-biotin-immunoperoxidase method
(DAKO Universal Kit, DAKO Corp., Carpinteria, CA, USA). Diamino-
benzidine was used as the final chromogen, and haematoxylin as the
nuclear counterstain. The monoclonal antibody C-reactive protein-8
displayed its reactivity against native and denatured C-reactive
protein without cross-reaction with human serum, amyloid P com-
ponent, human haptoglobin, human alpha-1-acid glyco-protein, and
human IgG. All specimens were analysed to assess cell number and
the immunoreactivity to C-reactive protein by a single investigator
who was blinded to patients’ characteristics. Atrial specimens were
scored as positive or negative for the presence or absence of
C-reactive protein.
Serum high-sensitivity C-reactive
protein assay
Serum high-sensitivity-C-reactive protein was assayed at baseline,
immediately after pulmonary vein isolation, and on Days 1 and 2 post-
operatively using a latex-enhanced immunonephelometric assay (BN II,
Siemens Diagnostic, Glasgow, DE, USA) as described elsewhere.21
Follow-up
After the procedure, patients continued anticoagulation with warfarin
to maintain an international normalized ratio of 2.0–3.0 for a minimum
of 3 months. In all patients, antiarrhythmic medications were continued
for 2 months after RFCA and they were chosen from one of sotalol,
propafenone, and flecainide. Amiodarone was not used after ablation.
Antiarrhythmic medications were discontinued in all patients after 2
months.
Early recurrence or late recurrence of AF was defined as AF occur-
ring within or beyond 2 months of RFCA, respectively.22 Patients had
scheduled clinical visits, 12-lead electrocardiography (ECG), and 24 h
Holter monitoring at 1, 2, 3, 6, and 12 months after catheter ablation.
Patients were also advised to monthly report any recurrence of symp-
toms; in this case, 24 h Holter monitoring was promptly obtained.
Recurrences were based on patient reporting, Holter, and ECG data.
The mean follow-up time for all patients in this study was 17+8
months.
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Statistical analysis
Continuous variables are reported as the mean value + standard devi-
ation (SD) or the median value and range for skewed distributions,
whereas categorical variables as absolute frequencies and percentages.
Comparisons between groups were performed with the unpaired
Student t test, the Mann–Whitney U test, or x2 test as appropriate.
All tests were two sided, and a value of P, 0.05 was settled for stat-
istical significance. Statistical analyses were performed by STATA 10.0
(Stata Corporation, College Station, TX, USA) statistical package.
Results
Clinical findings
Baseline characteristics of patients with paroxysmal or persistent
AF with adequate atrial samples are shown in Table 1. No signifi-
cant differences were observed between the two groups with
regard to age, gender, or prevalence of hypertension, coronary
artery disease, or use of statin, angiotensin-converting enzyme
inhibitors, or angiotensin receptor blockers, beta-blockers, amio-
darone, IC antiarrhythmic agents. Early recurrence of AF rates
was 26% among patients with paroxysmal AF and 38% among
patients with persistent AF. After a mean follow-up of 17+ 8
months, late recurrence of AF rates were 40% among patients
with paroxysmal AF and 13% among patients with persistent AF.
Histological findings and clinical
correlates
A total of 23 out of 70 atrial specimens from patients with AF were
adequate for pathological evaluation for a 32% yield (Figure 1A and B).
The presence of atrial cardiomyocytes was confirmed by histologi-
cal analysis performed by a blinded expert pathologist. Of note,
atrial specimens could not be obtained from any of the five
patients in whom trans-septal puncture was performed with
atrial radiofrequency current delivery to cross-resistant interatrial
septum.23 Atrial specimens from 4 (40%) out of 10 patients with
left-sided accessory pathways were adequate for immunostaining.
The number of isolated atrial cardiomyocytes per slide ranged
from a minimum of 60 to a maximum of 120 cells. More than
90% of isolated atrial cardiomyocytes retained cellular and
nuclear integrity. Atrial cardiomyocytes appeared normal in
size and structure in all patients with AF and in the control
group (Figure 1C–F). Immunohistochemical analysis revealed
C-reactive protein staining in 13 out of the 23 atrial specimens
from patients with AF, with specific localization of C-reactive
protein within the cytoplasm of atrial cardiomyocytes
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Table 1 Baseline characteristics of patients with paroxysmal and persistent atrial fibrillation
Paroxysmal AF (n 15) Persistent AF (n 8) P
Male gender, n (%) 10 (67) 6 (75) 1
Age 61+11 59+9 0.65
AF duration (years) 5.6+3.5 6.6+6 0.67
Lone AF, n (%) 8 (53) 6 (74) 0.39
Structural heart disease
Hypertensive cardiomiopathy, n (%) 6 (40) 1 (13) 0.35
Hypertrophic cardiomiopathy, n (%) 1 (7) 0 (0) 1
Valvular heart disease, n (%) 0 (0) 1 (13) 0.35
Echocardiographic parameters
Left atrial diameter (mm) 43.8+7 44.8+7.9 0.77
Left atrial volume (mL) 91.1+23.2 98.8+32.8 0.56
LVEF (%) 60.2+7.2 53.9+8.2 0.08
CT parameters
Left atrial volume (mL) 154.5+103.6 161.4+69.5 0.85
Procedure time (min) 271.2+58.1 282.9+51.9 0.58
Pre-ablation medication
Beta-blockers, n (%) 3 (20) 5 (63) 0.07
Amiodarone, n (%) 4 (27) 4 (50) 0.37
IC antiarrhythmic agents, n (%) 6 (40) 6 (63) 0.19
Statin, n (%) 3 (20) 1 (13) 0.62
ACEIs/ARB, n (%) 9 (60) 4 (57) 0.68
Early atrial fibrillation recurrence (ERAF), n (%) 4 (26) 3 (38) 0.66
Late atrial fibrillation recurrence (LRAF), n (%) 6 (40) 1 (13) 0.34
Follow-up (months) 10+6 14+8 0.23
Values are presented as mean + SD, or n (%).
AF, atrial fibrillation; LVEF, left ventricular ejection fraction; CT, computed tomography; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers.
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(Figure 1C and D). C-reactive protein immunostaining was absent
in all four atrial specimens of patients with left-sided accessory
pathways (Figure 1E and F).
The characteristics of patients according to the presence or
absence of C-reactive protein in atrial specimens are depicted in
Table 2. Mean age, presence of AF at the time of pulmonary vein
isolation, incidence of structural heart disease, echocardiographic,
and CT left atrial parameters were similar between patient positive
or negative for atrial tissue C-reactive protein. The percentage of
patients taking statins and angiotensin-converting enzyme inhibi-
tors also did not differ between atrial tissue C-reactive protein-
positive and C-reactive protein-negative groups. Conversely, a
higher proportion of patients positive for atrial tissue C-reactive
protein presented paroxysmal AF as compared with those negative
for tissue C-reactive protein (85 vs. 40%, P ¼ 0.02) (Figure 2). Also,
the rate of late recurrence of AF was higher in patients positive for
atrial tissue C-reactive protein as compared with those negative
for atrial tissue C-reactive protein, although this difference
achieved borderline significance (46 vs. 10%, P ¼ 0.06), while the
rate of early recurrence of AF was similar in patients positive or
negative for tissue C-reactive protein (Table 2).
Serum high-sensitivity C-reactive
protein levels
Among patients with AF, high-sensitivity-C-reactive protein levels
significantly increased from baseline to 24 and 48 h post-
operatively (baseline: median 1.725 mg/L, range 0.08–94 mg/L;
immediately post-RFCA: median 1.9 mg/L, range 0.08–12 mg/L;
24 h after RFCA: median 15.6 mg/L, range 7.84–211 mg/L; 48 h
after RFCA: median 39.3 mg/L, range 16.6–183 mg/L; all P,
0.001) (Figure 3). At each time point, no difference was observed
between patients positive or negative for tissue C-reactive
protein (Figure 4A), with paroxysmal or persistent AF (Figure 4B),
with or without late recurrence of AF, with or without early recur-
rence of AF.
Discussion
This study demonstrates the feasibility of harvesting atrial cardio-
myocytes by trans-septal catheterization. Atrial EMB in patients
with AF should be avoided, as recommended by a recent AHA/
ACC/ESC scientific statement because of safety concerns.10 In
Figure 1 Atrial cardiomyocytes isolated by trans-septal assembly washing. (A, B) Serial sections of isolated atrial cardiomyocytes were stained
with haematoxylin/eosin (original magnification 4×); (C, D) Atrial cardiomyocytes of patients with atrial fibrillation were immunohistochemically
stained with C-reactive protein antibodies. Positive staining for C-reactive protein is noted as brown in the cytoplasm with diffuse pattern of
localization (original magnification 20×); (E, F) negative staining for C-reactive protein was found in atrial cardiomyocytes of patients with left-
sided accessory pathways (original magnification 20×).
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contrast to the risks associated with this procedure, trans-septal left
heart catheterization is a safe technique and its clinical use is expand-
ing. Early experience with small numbers of patients demonstrated
the safety of performing trans-septal catheterization for ablation of
accessory pathways and atrial tachycardias.11 In recent series, includ-
ing over 5000 patients most of whom underwent ablation of AF,
complication rates associated with trans-septal access were
,1%.12 With the advent of intracardiac echocardiography, the
success rate in trans-septal catheterization has been reported to
reach 100%; thus, this technique is routinely utilized in patients
undergoing catheter ablation of AF or of left-sided accessory
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Table 2 Demographics and instrumental findings of patients with and without atrial tissue C-reactive protein
Atrial tissue C-reactive protein
Negative (n 10)
Atrial tissue C-reactive protein
Positive (n13)
P
Male gender, n (%) 6 (60) 10 (77) 0.4
Age (years) 64+5 57+12 0.08
Paroxysmal atrial fibrillation, n (%) 4 (40) 11 (85) 0.009*
Persistent atrial fibrillation, n (%) 6 (60) 2 (15) 0.009*
Atrial fibrillation at the time of catheter
ablation, n (%)
5 (50) 8 (62) 0.6
Lone atrial fibrillation, n (%) 7 (70) 7 (54) 0.5
Structural heart disease, n (%) 3 (30) 6 (46) 0.5
Echocardiographic parameters
Left atrial diameter (mm) 47+2 42+8 0.3
Left atrial volume (mL) 107+22 85+25 0.1
LVEF (%) 57+9 58+7 1
CT Left atrial volume (mL) 155+29 160+106 0.4
hs C-reactive protein serum levels (mg/dL)
Pre-ablation 2.1 (1.2–2.5) 1.3 (0.8–6.8) 0.8
Post-ablation 2.4 (1.8–3.2) 1.6 (0.8–1.9) 0.07
24 h after ablation 15.2 (10.7–18.2) 18 (13.4–20.2) 0.4
48 h after ablation 39.7 (28.2–40.9) 38 (28.9–41) 0.7
Early atrial fibrillation recurrence (ERAF), n (%) 3 (30) 4 (30) 0.9
Late atrial fibrillation recurrence (LRAF), n (%) 1 (10) 6 (46) 0.06
Values are presented as mean + SD, median (interquartile range), or n (%). LVEF, left ventricular ejection fraction; CT, computed tomography; hs, high sensitivity.
*Denotes statistical significance.
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Figure 3 Temporal trend of serum high-sensitivity C-reactive
protein (CRP) in all patients with atrial fibrillation. High-sensitivity
C-reactive protein was assayed at baseline (pre), immediately
after pulmonary vein isolation (post), and at 24 h and 48 h after
radiofrequency catheter ablation. Asterisk indicates P, 0.001
vs. pre-operative C-reactive protein assay (pre), Double asterisk
indicates P, 0.001 vs. pre and vs. 24 h.
90
80
70
60
50
40
30
20
10
0
Atrial tissue CRP positive Atrial tissue CRP negative
(%)
*
Paroxysmal AF Persistent AF
*
Figure 2 Intracytoplasmic C-reactive protein (CRP) and diag-
nosis of atrial fibrillation. Atrial specimens (%) positive and nega-
tive for tissue C-reactive protein in patients with diagnosis of
paroxysmal and persistent atrial fibrillation (AF). Asterisk indi-
cates all P ¼ 0.02.
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pathway.14–16 Accordingly, no complication associated with trans-
septal catheterization was observed in our study.
An atrial tissue specimen as by-product of routine trans-septal
puncture was suitable for immunohistochemistry only in 32 and
in 40% of patients with AF and with left-sided accessory pathways,
respectively. Interestingly, positivity for C-reactive protein in atrial
cardiomyocytes was not found in any of the four atrial specimens
from patients with left accessory pathways, whereas atrial tissue
C-reactive protein was significantly more frequent in patients
with paroxysmal AF than in patients with persistent AF. Further-
more, we observed a trend for an association between positivity
for atrial tissue C-reactive protein and late recurrence of AF.
An increasing body of evidence links atrial inflammation to at
least some types of AF, as non-valvular AF,5 lone paroxysmal
AF4, and AF associated with pericarditis.3,24 Among patients with
lone paroxysmal AF, results of atrial EMB demonstrated cardio-
myopathic alterations, such as atrial myocarditis, patchy fibrosis,
myocyte hypertrophy, and vacuolar degeneration of atrial myo-
cytes due to an extensive myofibrillolysis.4 In particular, Frustaci
et al.4 found atrial inflammatory lymphomononuclear infiltrates in
66% of patients with lone AF and normal histology in 11 atrial
specimens from WPW patients. In this study, atrial EMB was per-
formed in the septal region of the right atrium, from areas adjacent
to fossa ovalis. Our atrial specimens were also obtained from fossa
ovalis. Atrial musculature in the fossa ovalis consists of muscular
bands isolated by fatty tissue from the endocardium of the right
and left atrium.25
Our population also was predominantly composed of lone AF
patients (53% of patients with paroxysmal AF and 74% of patients
with persistent AF). The higher proportion of atrial C-reactive
protein-positive specimens in paroxysmal AF than in persistent
AF group may be an initial feature of myocardial damage via acti-
vation of the complement system, opsonization, chemotaxis, and
activation of inflammatory cells by this acute phase protein.26,27
A recent study by cardiac magnetic resonance demonstrated
atrial delayed enhancement, a marker of fibrosis more frequently
in persistent AF as compared with paroxysmal AF. Thus, in parox-
ysmal AF the role of other mechanisms as cellular dysfunction
driven by inflammation may precede the development of fibrosis.28
In this setting of AF, atrial tissue C-reactive protein may directly
contribute to these functional mechanisms acting as an opsonin
and participating in the clearance of apoptotic myocyte.29
Myocyte loss is typically accompanied by replacement fibrosis.
Thus, local inflammatory response in the atrium of patients with
paroxysmal AF may be the initial part of the structural remodelling,
which progresses to atrial fibrosis in persistent AF.28 Of note,
C-reactive protein has been shown to localize also in ventricular
cardiomyocytes after acute myocardial infarction30– 32 and in ven-
tricular myocardium of patients with non-ischaemic dilated cardio-
myopathy.33 In ischaemic ventricular cardiomyocytes, C-reactive
protein localization pattern suggested that this protein recognized
membrane epitopes expressed on jeopardized myocytes thus
binding to sarcolemma.31 In contrast, in ventricular myocardium
of patients with non-ischaemic dilated cardiomyopathy there was
a significant expression of C-reactive protein and tumour necrosis
factor alpha as proinflammatory mediators.33 The results of our
study do not allow deducing whether atrial tissue C-reactive
protein is taken in or synthesized by atrial cardiomyocytes.
It is worth noting that in our study the presence of C-reactive
protein in human atrial tissue was unrelated to serum
high-sensitivity-C-reactive protein levels in AF patients. In particu-
lar, serum C-reactive protein levels were similar in paroxysmal and
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Figure 4 (A) High-sensitivity C-reactive protein (CRP) was assayed at baseline (pre), immediately after pulmonary vein isolation (post), and at
24 h and 48 h after radiofrequency catheter ablation in patients positive and negative for intracytoplasmic C-reactive protein (P ¼ 0.7). (B) High-
sensitivity C-reactive protein was assayed at baseline (pre), immediately after pulmonary vein isolation (post), and at 24 h and 48 h after radio-
frequency catheter ablation in patients with diagnosis of paroxysmal and persistent atrial fibrillation (P ¼ 0.2).
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persistent AF. In concordance with recent evidence,34 serum
high-sensitivity-C-reactive protein levels significantly increased
from baseline to 48 h after catheter ablation, irrespective of the
type of AF. This post-operative elevation of serum C-reactive
protein is likely caused by the extensive amount of left atrial
tissue involved in RFCA of AF, whereas the presence of atrial
tissue C-reactive protein was assessed before RFCA.
Interestingly, Marcus et al.35 by sampling from left atrium and
coronary sinus demonstrated intracardiac sequestration of
C-reactive protein in patients with AF as compared with patients
with sinus rhythm. Consistent with these findings, we could
hypothesize a systemic origin of atrial tissue C-reactive protein.
In our study, we found a borderline association between atrial
tissue C-reactive protein and late recurrence of AF, but a larger
sample size is needed to demonstrate the predictive role of
atrial tissue C-reactive protein on late recurrence of AF. In con-
trast, serum high-sensitivity-C-reactive protein levels were similar
in patients experiencing early and late recurrence of AF. This
finding was in concordance with those reported by Letsas
et al.36 in patients with paroxysmal and persistent AF in which
high-sensitivity-C-reactive protein was not an independent predic-
tor of arrhythmia relapse. Lellouche et al.34 demonstrated that
serum C-reactive protein levels were similar in patients with and
without late recurrences. Accordingly, in a large population of
patients with AF, Verma et al.22 found similar levels of serum
C-reactive protein levels in patients with and without late arrhyth-
mia recurrences.
The main limitation of this study is represented by the small
sample size. Thus, our data should be considered as hypothesis
generating. Of note, no power calculation could be performed as
no previous study addressed this issue. A second limitation is
sampling error enhanced by the small amount of tissue that was
possible to obtain from each patient. In this regard, atrial cardio-
myocytes yield from specimens obtained by trans-septal assembly
washing was not compared with conventional atrial EMB.
Additional technical issues could be performed in order to
increase atrial cell yield. A third limitation is failure to detect
asymptomatic episodes of AF during follow-up, with consequent
underestimation of the incidence of recurrences.
In conclusion, this study describes a novel technique for harvest-
ing atrial cardiomyocytes in patients with AF undergoing trans-
septal catheterization for pulmonary vein isolation. The chance
to obtain atrial biopsy by washing trans-septal assembly may
advance our understanding of cellular and molecular mechanisms
of AF initiation and progression. In our study, atrial inflammation,
as assessed by the identification of C-reactive protein in isolated
atrial cardiomyocytes, was more frequent in paroxysmal rather
than in persistent AF patients, potentially unmasking an early func-
tional damage of atrial cardiomyocytes leading to atrial fibrosis.
Conflict of interest: none declared.
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